$STXS

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this f

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001289340 0001289340 2026-07-07 2026-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report

Stereotaxis (STXS) reported Q1 2026 revenue of $6.3M (down from $7.5M), with system revenue $1.3M and recurring revenue $5.0M. Operating loss was $6.0M; cash was $14.6M with no debt. The company cited legacy J&J catheter wind-down and said MAGiC demand exceeds supply, targeting 500 catheters/month by year-end. Citizens reiterated “Market Outperform” and a $4.00 price target.

Stereotaxis (NYSE: STXS) announced its first quarter 2026 financial results and business updates, highlighting significant regulatory approvals for its MAGiC catheter and Synchrony system, and the acquisition of Robocath. While revenue for Q1 2026 was $6.3 million, down from $7.5 million in the prior year, the company anticipates double-digit revenue growth for the full year 2026, exceeding $40 million, driven by increased manufacturing and placements of its new products. Stereotaxis emphasized its strategic goal to integrate Robocath and achieve profitability without substantial investor dilution.

Surgical robotics provider Stereotaxis (STXS) reported its Q1 revenue, which fell short of analyst estimates. The news was sourced from Reuters. This brief update suggests a potential negative outlook for the company's financial performance.

Stereotaxis, Inc. (STXS) saw significant regulatory milestones in Q1 2026, including FDA approvals and the acquisition agreement with Robocath. Despite a year-over-year revenue decline in Q1, the company anticipates double-digit growth for 2026 driven by increasing manufacturing capacity and the traction of new products. This information is based on an AI-generated summary of an SEC 8-K Current Report.

The article highlights Stereotaxis, Inc. (NYSE: STXS) as one of the best robotics stocks under $30, citing its FDA-approved MAGiC catheter and recent acquisition of European robotics company Robocath. Stereotaxis's MAGiC system enables precise, computer-controlled catheter movement for minimally invasive cardiac ablation, successfully treating complex heart cases. The acquisition of Robocath is expected to provide Stereotaxis with commercial foothold in Europe and enhance its robotic surgical platform.

Stereotaxis, Inc. has introduced its TeleRobotic Test Drive, enabling remote access to its RoboticEP technology for prospective clients and partners. This initiative aims to increase accessibility and adoption of robotic electrophysiology solutions. The company previously announced plans to unveil new robotic EP technology at upcoming events like EHRA2026, highlighting its focus on innovation in remote and robotic EP.

Stereotaxis Inc. (STXS) reported a Q4 loss of $0.06 per share, in line with Zacks Consensus Estimate, and an earnings surprise of +5.21%. However, the company missed revenue estimates with $8.64 million, compared to the expected $9.15 million. The stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.